# A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake

> **NCT02128581** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 3 (actual)

## Conditions studied

- Obesity
- Diabetes
- Roux-en-Y Gastric Bypass

## Interventions

- **DRUG:** Exendin-9,39
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT02128581
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2016-03
- **Final completion:** 2019-07
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2019-10-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02128581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02128581, "A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02128581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*